Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) | Acute Coronary Syndromes | JAMA | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
Grady D, Applegate W, Bush TL.  et al.  Heart and estrogen/progestin replacement study (HERS): design, methods and baseline characteristics.  Control Clin Trials.1998;19:314-335.Google Scholar
Hulley S, Grady D, Bush T.  et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.  JAMA.1998;280:605-613.Google Scholar
Simon JA, Hsia J, Cauley JA.  et al.  Postmenopausal hormone therapy and risk of stroke.  Circulation.2001;103:638-642.Google Scholar
Hsia J, Simon JA, Lin F.  et al.  Peripheral arterial disease in a randomized trial of estrogen with progestin in women with coronary heart disease.  Circulation.2000;102:2228-2232.Google Scholar
Hulley SB, Bittner V, Furberg C.  et al.  Hormone treatment: misconceptions and agreements.  Eur Heart J.2002;23:89-91.Google Scholar
Hulley S, Furberg C, Barrett-Connor E.  et al. for the HERS Research Group.  Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).  JAMA.2002;288:58-66.Google Scholar
Shlipak MG, Elmouchi DA, Herrington DM, Lin F, Grady D, Hlatky MA. The incidence of unrecognized myocardial infarction in women with coronary heart disease.  Ann Intern Med.2001;134:1043-1047.Google Scholar
Multiple Risk Factor Intervention Trial Research Group.  Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial: findings related to a priori hypotheses of the trial.  JAMA.1990;263:1795-1801.Google Scholar
Canner PL, Berge KG, Wenger NK.  et al.  Fifteen-year mortality in Coronary Drug Project patients: long-term benefit with niacin.  J Am Coll Cardiol.1986;8:1245-1255.Google Scholar
Pedersen TR, Wilhelmsen L, Faergeman O.  et al.  Follow-up study of patients randomized in the Scandanavian Simvastatin Survival Study (4S) of cholesterol lowering.  Am J Cardiol.2000;86:257-262.Google Scholar
Rossouw JE. Early risk of cardiovascular events after commencing hormone replacement therapy.  Curr Opin Lipidol.2001;12:371-375.Google Scholar
Lenfant C. Preliminary trends in the Women's Health Initiative [press release]. Bethesda, Md: National Heart, Lung, and Blood Institute; March 24, 2000.
 WHI [Women's Health Initiative] HRT Update. Available at: Accessibility verified June 4, 2002.
Wenger NK, Knatterud GL, Canner PL. Early risks of hormone therapy in patients with coronary heart disease.  JAMA.2000;284:41-43.Google Scholar
Alexander KP, Newby LK, Hellkamp AS.  et al.  Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up.  J Am Coll Cardiol.2001;38:1-7.Google Scholar
Heckbert SR, Kaplan RC, Weiss NS.  et al.  Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy.  Arch Intern Med.2001;161:1709-1713.Google Scholar
Grady D, Wenger NK, Herrington D.  et al.  Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study.  Ann Intern Med.2000;132:689-696.Google Scholar
Ridker P. Intrinsic fibrinolytic capacity and systemic inflammation: novel risk factors for arterial thrombotic disease.  Haemostasis.1997;27(suppl 1):2-11.Google Scholar
Furberg C, Vittinghoff E, Davidson M.  et al.  Subgroup interactions in the Heart and Estrogen/progestin Replacement Study: lessons learned.  Circulation.2002;105:917-922.Google Scholar
Psaty BM, Smith NL, Lemaitre RN.  et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal MI in postmenopausal women.  JAMA.2001;285:906-913.Google Scholar
Herrington DM, Reboussin DM, Brosnihan KB.  et al.  Effects of estrogen replacement on the progression of coronary artery atherosclerosis.  N Engl J Med.2000;343:522-529.Google Scholar
Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke.  N Engl J Med.2001;345:1243-1249.Google Scholar
Mosca L, Collins P, Herrington DM.  et al.  Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.  Circulation.2001;104:499-503.Google Scholar
Original Contribution
July 3, 2002

Cardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II)

Author Affiliations

Author Affiliations: Departments of Epidemiology and Biostatistics (Drs Grady, Hulley, and Vittinghoff) and Medicine (Dr Waters), University of California, San Francisco; Department of Internal Medicine/Cardiology, Wake Forest University School of Medicine, Winston-Salem, NC (Dr Herrington); Division of Cardiovascular Disease, Department of Medicine, University of Alabama, Birmingham (Dr Bittner); Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, Md (Dr Blumenthal); Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill (Dr Davidson); Departments of Health Research and Policy, and of Medicine, Stanford University School of Medicine, Palo Alto, Calif (Dr Hlatky); Department of Medicine, George Washington University, Washington, DC (Dr Hsia); Division of Cardiology, Cedars Sinai and UCLA School of Medicine, Los Angeles, Calif (Dr Khan); Department of Medicine, Baylor College of Medicine, Houston, Tex (Dr Herd); Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC (Dr Newby); and Department of Medicine, Emory University School of Medicine, Atlanta, Ga (Dr Wenger).

JAMA. 2002;288(1):49-57. doi:10.1001/jama.288.1.49

Context The Heart and Estrogen/progestin Replacement Study (HERS) found no overall reduction in risk of coronary heart disease (CHD) events among postmenopausal women with CHD. However, in the hormone group, findings did suggest a higher risk of CHD events during the first year, and a decreased risk during years 3 to 5.

Objective To determine if the risk reduction observed in the later years of HERS persisted and resulted in an overall reduced risk of CHD events with additional years of follow-up.

Design and Setting Randomized, blinded, placebo-controlled trial of 4.1 years' duration (HERS) and subsequent unblinded follow-up for 2.7 years (HERS II) conducted at outpatient and community settings at 20 US clinical centers.

Participants A total of 2763 postmenopausal women with CHD and average age of 67 years at enrollment in HERS; 2321 women (93% of those surviving) consented to follow-up in HERS II.

Intervention Participants were randomly assigned to receive 0.625 mg/d of conjugated estrogens and 2.5 mg of medroxyprogesterone acetate (n = 1380), or placebo (n = 1383) during HERS; open-label hormone therapy was prescribed at personal physicians' discretion during HERS II. The proportions with at least 80% adherence to hormones declined from 81% (year 1) to 45% (year 6) in the hormone group, and increased from 0% (year 1) to 8% (year 6) in the placebo group.

Main Outcome Measures The primary outcome was nonfatal myocardial infarction and CHD death. Secondary cardiovascular events were coronary revascularization, hospitalization for unstable angina or congestive heart failure, nonfatal ventricular arrhythmia, sudden death, stroke or transient ischemic attack, and peripheral arterial disease.

Results There were no significant decreases in rates of primary CHD events or secondary cardiovascular events among women assigned to the hormone group compared with the placebo group in HERS, HERS II, or overall. The unadjusted relative hazard (RH) for CHD events in HERS was 0.99 (95% confidence interval [CI], 0.81-1.22); HERS II, 1.00 (95% CI, 0.77-1.29); and overall, 0.99 (0.84-1.17). The overall RHs were similar after adjustment for potential confounders and differential use of statins between treatment groups (RH, 0.97; 95% CI, 0.82-1.14), and in analyses restricted to women who were adherent to randomized treatment assignment (RH, 0.96; 95% CI, 0.77-1.19).

Conclusions Lower rates of CHD events among women in the hormone group in the final years of HERS did not persist during additional years of follow-up. After 6.8 years, hormone therapy did not reduce risk of cardiovascular events in women with CHD. Postmenopausal hormone therapy should not be used to reduce risk for CHD events in women with CHD.